Feb 3, 2026 04:07PM Sangamo presents Fabry disease gene therapy data at medical symposium

Feb 3, 2026 09:11AM Sangamo Therapeutics prices $25 million stock offering at $0.47 per share

Feb 3, 2026 08:59AM Sangamo Therapeutics names interim CFO after financial officer departure

Dec 18, 2025 08:05AM Sangamo starts FDA submission for gene therapy to treat Fabry disease

Nov 21, 2025 08:05AM Sangamo gets FDA nod for rolling BLA submission of Fabry disease therapy

Nov 7, 2025 03:51AM Barclays Downgrades Sangamo BioSciences (SGMO) to Equalweight

Sep 5, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Sangamo BioSciences (SGMO)

Sep 4, 2025 08:05AM Sangamo presents data on Fabry disease gene therapy ahead of FDA filing

Aug 7, 2025 04:07PM Sangamo Therapeutics (SGMO) Misses Q2 EPS by 6c, reiterates guidance

Jun 25, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Sangamo BioSciences (SGMO)

Jun 24, 2025 08:05AM Sangamo Therapeutics (SGMO) Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

May 29, 2025 07:04AM H.C. Wainwright Reiterates Buy Rating on Sangamo BioSciences (SGMO)

May 13, 2025 06:56AM Sangamo BioSciences (SGMO) PT Lowered to $1.50 at Jefferies

May 6, 2025 08:31AM Sangamo Therapeutics (SGMO) Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Apr 8, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Sangamo BioSciences (SGMO)

Apr 3, 2025 04:01PM Sangamo Therapeutics (SGMO) Announces Capsid License Agreement With Lilly (LLY) to Deliver Genomic Medicines for Diseases of the Central Nervous System

Mar 19, 2025 09:15AM Truist Reiterates Buy Rating on Sangamo BioSciences (SGMO), Removes PT

Mar 18, 2025 04:49AM Sangamo BioSciences (SGMO) PT Lowered to $2 at Jefferies

Mar 17, 2025 04:05PM Sangamo Therapeutics (SGMO) Misses Q4 EPS by 1c

Feb 6, 2025 08:06AM Sangamo Therapeutics (SGMO) Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Jan 23, 2025 11:56AM Sangamo BioSciences (SGMO) PT Lowered to $5 at Truist Securities

Jan 2, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Sangamo BioSciences (SGMO)

Dec 31, 2024 06:41AM Sangamo Therapeutics (SGMO) call put ratio 4.2 calls to 1 put into partnership terminated with Pfizer (PFE)

Dec 31, 2024 05:43AM Sangamo BioSciences (SGMO) PT Lowered to $2 at Wells Fargo

Dec 30, 2024 04:17PM Sangamo Therapeutics (SGMO) to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

Dec 13, 2024 06:07AM Truist Securities Upgrades Sangamo BioSciences (SGMO) to Buy

Nov 19, 2024 04:15PM Sangamo Therapeutics (SGMO) Announces FDA Clearance of IND Application for ST-503

Nov 12, 2024 04:02PM Sangamo Therapeutics (SGMO) Tops Q3 EPS by 6c, provides guidance

Nov 5, 2024 06:43AM Sangamo BioSciences (SGMO) PT Raised to $10 at H.C. Wainwright

Oct 23, 2024 07:58AM TD Cowen Reiterates Buy Rating on Sangamo BioSciences (SGMO)

Oct 22, 2024 08:05AM Sangamo Therapeutics (SGMO) Announces Alignment With FDA on Accelerated Approval Pathway for ST-920

Aug 6, 2024 04:40PM Sangamo Therapeutics (SGMO) Misses Q2 EPS by 3c

Aug 6, 2024 08:07AM Sangamo Therapeutics (SGMO) Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

Jul 24, 2024 06:57AM Sangamo Therapeutics (SGMO) Reports on Pfizer’s (PFE) Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate